Kosacka Monika, Jankowska Renata
Katedra i Klinika Pulmonologii i Nowotworow, Wroclaw, Poland.
Pneumonol Alergol Pol. 2007;75(4):317-23.
Cytokeratins are important part of cytoskeleton. Cytokeratin 19 (CK 19) belongs to type I cytokeratins. Lung cancer is currently most frequently diagnosed neoplasm in males in many developed countries and in Poland. The prognosis in lung cancer remains unfavourable. The aim of this study was to evaluate the prognostic value of cytokeratin 19 expression in non-small cell lung cancer.
We examined the degree of cytokeratin 19 expression in 94 patients with non-small cell lung cancer, who had undergone surgery. The group consisted of 64 men and 30 women. The mean age was 59,12 +/- 8,61 years. Histological diagnosis was squamous cell carcinoma in 59 patients, adenocarcinoma in 26 patients, large cell carcinoma in 5 patients and non-small cell lung cancer without determination of the subtype in 4 patients. Cytokeratin 19 expression was examined immunohistochemically with Monoclonal Mouse Anti-Human Cytokeratin 19 Clone BA 17 DAKO M 0772. All patients were observed for 24 months. 45 patients (48%) survived, 49 died.
In all examined tumors we observed positive cytoplasmatic staining of cytokeratin 19. In 41 cases (44%) it was weak staining (CK 1), in 35 (37%) medium (CK 2) and in 18 (19%) strong one (CK 3). We demonstrated higher expression of cytokeratin 19 in these patients, who survived 2 years (p = 0,003). We also observed relationship between higher expression of CK 19 and survival in patients with squamous cell cancer, but there was no correlation with survival in patients with adenocarcinoma.
Our results suggest that the degree of cytokeratin 19 expression could be a new prognostic factor in non-small cell lung cancer. Cytokeratin 19 expression has prognostic value in patients with squamous cell lung cancer but not in patients with adenocarcinoma.
细胞角蛋白是细胞骨架的重要组成部分。细胞角蛋白19（CK 19）属于I型细胞角蛋白。在许多发达国家以及波兰，肺癌是目前男性中最常被诊断出的肿瘤。肺癌的预后仍然不容乐观。本研究的目的是评估细胞角蛋白19表达在非小细胞肺癌中的预后价值。
我们检测了94例接受手术的非小细胞肺癌患者的细胞角蛋白19表达程度。该组包括64名男性和30名女性。平均年龄为59.12±8.61岁。组织学诊断为鳞状细胞癌59例，腺癌26例，大细胞癌5例，4例未确定亚型的非小细胞肺癌。采用鼠抗人细胞角蛋白19单克隆抗体克隆BA 17（DAKO M 0772）通过免疫组织化学方法检测细胞角蛋白19表达。所有患者均观察24个月。45例（48%）存活，49例死亡。
在所有检测的肿瘤中，我们观察到细胞角蛋白19的细胞质呈阳性染色。41例（44%）为弱阳性（CK 1），35例（37%）为中度阳性（CK 2），18例（19%）为强阳性（CK 3）。我们发现存活2年的患者中细胞角蛋白19表达较高（p = 0.003）。我们还观察到CK 19高表达与鳞状细胞癌患者的生存之间存在关联，但与腺癌患者的生存无相关性。
我们的结果表明，细胞角蛋白19的表达程度可能是非小细胞肺癌的一个新的预后因素。细胞角蛋白19表达在鳞状细胞肺癌患者中有预后价值，但在腺癌患者中无此价值。
